Novacyt S.A. (EPA:ALNOV)

Market Cap	36.69M +16.9%
Revenue (ttm)	22.96M +2.0%
Net Income	-26.23M
EPS	-0.37
Shares Out	72.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,262
Open	0.5200
Previous Close	0.5100
Day's Range	0.5050 - 0.5200
52-Week Range	0.2900 - 1.0400
Beta	1.12
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 25, 2026

About Novacyt

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 216
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNOV

Financial Performance

In 2025, Novacyt's revenue was 20.03 million, an increase of 2.03% compared to the previous year's 19.63 million. Losses were -22.88 million, -45.20% less than in 2024.

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error